While mTOR and TGF‐β signaling inhibitors and drugs targeting metabolic pathways have shown promise in BC therapy,52, 53, 54, 55, 56 their efficacy often encounters challenges such as tumor heterogeneity.29 This evidence concerns the gene MTOR and breast cancer.